Faculty Profile

Tamara Vokes
Section of Endocrinology, Diabetes and Metabolism
Professor of Medicine (Part-Time)
tvokes@bsd.uchicago.edu
Referring Physician Access Line: 1-877-DOM-2730
Director, Osteoporosis Clinic

Academic Interests

Dr. Vokes' research interest is in the area of osteoporosis and metabolic bone disease. In the area of osteoporosis, Dr. Vokes has investigated novel approaches to refining the assessment of fracture risk. Among those, she has pioneered the clinical application of Vertebral Fracture Assessment (VFA) in improving identification of patients with highest fractures risk who may need the most aggressive therapeutic approach. Dr. Vokes has also examined racial differences in fracture risk and delineated the risk factors which may differ between Caucasian and African American subjects. In the area of metabolic bone disease, Dr. Vokes has participated in multicenter clinical trials using replacement therapy with PTH and its analogues for patients with hypoparathyroidism, the last hormone deficiency syndrome for which hormone replacement therapy was not available until recently.
 

Clinical Interests

Dr. Vokes has a clinical program that focuses on osteoporosis and other metabolic bone diseases, particularly hyper- and hypoparathyroidism. Patients are referred from within the institution as well from the Chicago metropolitan area and the Midwest. As a result, the fellows rotating through this clinic are exposed to wide range of bone pathology
 

Publications

  • Using opportunistic screening with abdominal CT to identify osteoporosis and osteopenia in patients with diabetes. Jain RK, Lee E, Mathai C, Dako F, Gogineni P, Weiner MG, Vokes T. Osteoporos Int. 2020 Jul 5. doi:10.1007/s00198-020-05521-x. Epub ahead of print. PMID: 32623489.
  • Diabetes-Related Fracture Risk Is Different in African Americans Compared With Hispanics and Caucasians. Jain RK, Weiner MG, Zhao H, Williams KJ, Vokes T. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5729-5736. doi: 10.1210/jc.2019-00931. PMID: 31369094.
  • Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. Mannstadt M, Clarke BL, Bilezikian JP, Bone H, Denham D, Levine MA, Peacock M, Rothman J, Shoback DM, Warren ML, Watts NB, Lee HM, Sherry N, Vokes TJ.J Clin Endocrinol Metab. 2019 Nov 1;104(11):5136-5147. doi: 10.1210/jc.2019-01010. PMID: 31369089; PMCID: PMC6760337.
  • Quality of Life in Hypoparathyroidism. Endocrinol Metab Clin North Am. Vokes TJ. 2018 Dec;47(4):855-864. doi: 10.1016/j.ecl.2018.07.010. Epub 2018 Oct 11. Review. PubMed PMID: 30390818.
  • Quality of Life in Hypoparathyroidism. Vokes TJ. Endocrinol Metab Clin North Am. 2018 Dec;47(4):855-864. doi: 10.1016/j.ecl.2018.07.010. Epub 2018 Oct 11. PMID: 30390818.
For a complete list of publications click here:

Training

  • MD, 1977, University of Belgrade
  • Residency, 1982, Ravenswood Hospital, Internal Medicine
  • Fellowship, 1983, University of California, Endocrinology
  • Fellowship, 1985, The University of Chicago, Endocrinology